First Manhattan’s Indivior Pharmaceuticals INDV Stock Holding History

First Manhattan’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,315	Closed	-$49.6K	–	969
2024 Q1	$49.6K	Sell	2,315 -120	-5%	-$2.25K	﹤0.01%	894
2023 Q4	$37.2K	Sell	2,435 -100	-4%	-$1.78K	﹤0.01%	924
2023 Q3	$58.5K	Sell	2,535 -260	-9%	-$5.93K	﹤0.01%	840
2023 Q2	$66.5K	Buy	+2,795	New	+$64.1K	﹤0.01%	837

Other funds holding INDV

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

MGP

M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

First Manhattan's INDV Position: Q2 2024 in Review

First Manhattan sold out of Indivior Pharmaceuticals (INDV) in Q2 2024, closing a stake of 2,315 shares — an estimated $49.6K sold.

First Manhattan first reported a position in INDV in Q2 2023 and held it in 4 quarters. The position peaked at $66.5K in Q2 2023. 99 funds tracked by Wall St. Rank hold INDV as of Q2 2024.

First Manhattan reported no remaining Indivior Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
First Manhattan sold 2,315 Indivior Pharmaceuticals shares in Q2 2024, an estimated $49.6K.
First Manhattan first reported a position in Indivior Pharmaceuticals in Q2 2023 and held it in 4 quarters.
First Manhattan's Indivior Pharmaceuticals position peaked at $66.5K in Q2 2023.
99 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.